VivoSeq
Oncology

Central Nervous System Cancer

20

Pipeline Programs↗

1

Active Trials↗

12

Companies Involved↗

Central Nervous System Cancer is an emerging landscape with 20 programs across 12 companies. The most active players are Avyxa, Amgen, Eli Lilly. 8 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

15/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

2 programs

Phase 1Amgen logo

Amgen

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1E

Eastern Cooperative Oncology Group

1 program

Phase 1M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

84%

Small molecule

16 of 19 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody15%Protein / enzyme15%Gene therapy15%

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 95% of 20 pipeline programs.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
Completed·RRoswell Park Cancer Institute·Phase 1·NCT00053118·1 enrolled
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
Completed·HHerbert Irving Comprehensive Cancer Center·Phase 2·NCT00007982·30 enrolled
A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors
Active, not recruiting·Children's Oncology Group·Phase 3·NCT04939597·162 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)